But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show if twice daily oral dosing of ...

The announcement means the company will be pulling the plug on the CardinALS trial after its ALS drug failed to halt disease ...

PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...

Philadelphia dad Eric Brunner was diagnosed with amyotrophic lateral sclerosis, the fatal disease known as ALS. He wants to ...

In a new study of mouse cells, scientists found that both the biochemical and mechanical effects of exercise may help injured ...

PTC Therapeutics halts Utreloxastat development after ALS trial disappoints. Analysts highlight promising pipeline, including ...

A team from IIT-BHU is developing a revolutionary cell-based device using 3D bioprinting technology to potentially cure ...

PTC Therapeutics said on Tuesday it is discontinuing the development of its drug for a type of fatal neurodegenerative disease, as it failed to slow disease progression in a mid-stage trial. This ...

Bank of America Securities analyst Tazeen Ahmad maintained a Sell rating on PTC Therapeutics (PTCT – Research Report) yesterday and set a price ...

Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...

There are now at least two patients who have had Neuralink's brain chip implanted in their head. While there have been some ...

A team at IIT (BHU) is developing a revolutionary cell-based medical device using 3D bioprinting technology aimed at curing ...